The HEBP1 Knockout Jurkat Polyclonal Cells are a ready-to-use, CRISPR/Cas9-edited polyclonal population of Jurkat T lymphocytes engineered for loss-of-function studies of the HEBP1 gene. This knockout model is generated through targeted disruption of the HEBP1 locus, resulting in ablation of functional heme-binding protein 1 expression across a heterogeneous pool of edited alleles. The polyclonal format maintains a diverse genetic background while abolishing HEBP1 protein activity, offering a robust system for investigating heme-regulated cellular processes without the clonal variability associated with single-cell-derived lines. The product is supplied as a live cell population suitable for immediate downstream functional assays.
The parental Jurkat cell line is a human acute T-cell leukemia-derived line isolated from the peripheral blood of a patient with T-cell leukemia. These cells are extensively employed as a model system for T-lymphocyte biology, including signal transduction, apoptosis mechanisms, and HIV research. Jurkat cells exhibit constitutive activation of T-cell receptor-proximal signaling pathways, making them particularly useful for examining the interplay between intracellular heme dynamics and lymphocyte apoptosis. Their leukemic origin also provides a relevant context for studying how heme homeostasis disruptions may influence malignant T-cell survival and drug responses.
HEBP1 encodes a heme-binding protein implicated in intracellular heme trafficking and detoxification, with a proposed antioxidant function. Mechanistically, HEBP1 is regulated by cellular heme levels and oxidative stress stimuli, and it directly interacts with heme and cytochrome c, facilitating heme transfer to apoptotic effectors. Within the heme homeostasis and apoptosis network, HEBP1 operates upstream of cytochrome c and caspase activation, while also intersecting with key regulators such as HO-1, BCL2, and BAX. Disruption of HEBP1 is therefore expected to perturb heme distribution, potentially lowering the threshold for cytochrome c release and subsequent caspase-mediated apoptosis in response to oxidative or stress signals.
In the Jurkat T-cell leukemia background, HEBP1 knockout provides a physiologically relevant platform to dissect how heme availability modulates apoptosis and T-cell signaling. Given Jurkat cells are inherently primed for apoptotic responses through the extrinsic and intrinsic pathways, loss of HEBP1 may enhance sensitivity to death receptor ligands, chemotherapeutic agents, or oxidative stress insults. This model allows researchers to interrogate the crosstalk between heme homeostasis and lymphocyte survival, with implications for understanding heme-related disorders and T-cell malignancies.
This knockout product is ideally suited for a broad range of experimental applications, including heme homeostasis research, apoptosis pathway analysis, and T-cell signaling studies. Typical assays performed with these cells include Western blotting, RT-qPCR, heme quantification, cytochrome c release assays, apoptosis flow cytometry, caspase activity measurements, and reactive oxygen species detection. Additionally, the polyclonal population is valuable for drug screening campaigns targeting heme-dependent pathways or BCL2 family-regulated apoptosis. For further technical details or ordering information, please contact Ascent Research.
